Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CRVS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | CRVS Corvus Pharmaceuticals, Inc. | State Street Corporation | 3.33M | 4.0% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | CRVS Corvus Pharmaceuticals, Inc. | State Street Corporation | 4.47M | 5.3% | SCHEDULE 13G ↗ |
| Jul 27, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | BlackRock, Inc. | 6.33M | 7.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Steven A. Cohen | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Point72 Capital Advisors, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Point72 Asset Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | CRVS Corvus Pharmaceuticals, Inc. | Alex Silverstein | 6.83M | 7.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CRVS Corvus Pharmaceuticals, Inc. | Sirenia Capital Management LP | 6.83M | 7.5% | SCHEDULE 13G ↗ |
| Apr 27, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | BlackRock, Inc. | 5.39M | 6.4% | SCHEDULE 13G/A ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Sandra J. Horning | 1.19M | 1.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 | 1.19M | 1.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Richard A. Miller | 6.09M | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street Venture/Growth Fund VI LP | 236,128 | 0.3% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2018 Direct Venture/Growth Fund LP | 126,806 | 0.2% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2017 Direct Venture/Growth Fund LP | 87,668 | 0.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2016 Direct Venture/Growth Fund LP | 67,769 | 0.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2015 Direct Venture/Growth Fund LP | 69,864 | 0.1% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2014 Direct Fund LP | 736,033 | 0.9% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2013 Direct Fund LP | 541,133 | 0.6% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2012 Direct Fund LP | 715,361 | 0.9% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street 2011 Direct Fund LP | 694,854 | 0.8% | SCHEDULE 13D/A ↗ |
| Feb 5, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Adams Street Partners, LLC | 3.28M | 3.9% | SCHEDULE 13D/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G | CRVS Corvus Pharmaceuticals, Inc. | The Vanguard Group | 3.87M | 5.2% | SCHEDULE 13G ↗ |
| Jan 27, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Capital GP V LLC | 8.61M | 10.3% | SCHEDULE 13D/A ↗ |
| Jan 27, 2026 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC | 8.61M | 10.3% | SCHEDULE 13D/A ↗ |
| Oct 17, 2025 | SCHEDULE 13G | CRVS Corvus Pharmaceuticals, Inc. | BlackRock, Inc. | 4.02M | 5.4% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Robert Pohly | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Samlyn, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Samlyn Capital, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Robert Pohly | 4.07M | 6.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Samlyn, LP | 4.07M | 6.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Samlyn Capital, LLC | 4.07M | 6.0% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Capital GP V LLC | 9.79M | 12.2% | SCHEDULE 13D/A ↗ |
| May 14, 2025 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC | 9.79M | 12.2% | SCHEDULE 13D/A ↗ |
| May 1, 2025 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Capital GP V LLC | 9.79M | 13.8% | SCHEDULE 13D/A ↗ |
| May 1, 2025 | SCHEDULE 13D/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC | 9.79M | 13.8% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Robert Pohly | 6.67M | 9.8% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Samlyn, LP | 6.67M | 9.8% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Samlyn Capital, LLC | 6.67M | 9.8% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Sandra J. Horning | 1.77M | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 | 1.77M | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G/A (amended) | CRVS Corvus Pharmaceuticals, Inc. | Richard A. Miller | 5.22M | 7.7% | SCHEDULE 13G/A ↗ |
43 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 8:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances